AGLE Aeglea BioTherapeutics Inc.

7.5
-0.19  -2%
Previous Close 7.69
Open 7.68
Price To Book 2.82
Market Cap 179715855
Shares 23,962,114
Volume 72,294
Short Ratio
Av. Daily Volume 182,071

SEC filingsSee all SEC filings

  1. 8-K - Current report 181229393
  2. 8-K - Current report 181228818
  3. 8-K - Current report 181207030
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168246
  5. 8-K - Current report 181168223

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102
Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)
Phase 1/2 repeat dose data due 1H 2019. Phase 3 trial to be initiated 2Q 2019 with data due 1Q 2021.
Pegzilarginase (AEB1102)
Arginase I deficiency
Phase 1 dose escalation data presented at AACR April 15, 2018.
AEB1102
Solid tumors
Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102)
Solid tumors
Phase 1/2 top-line safety and clinical data due 4Q 2018.
Pegzilarginase (AEB1102) + KEYTRUDA
Small cell lung cancer (SCLC)

Latest News

  1. What Investors Should Know About Aeglea BioTherapeutics, Inc.’s (NASDAQ:AGLE) Financial Strength
  2. Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
  3. Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
  4. Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
  5. Report: Exploring Fundamental Drivers Behind Aeglea BioTherapeutics, Barnes & Noble Education, GSI Technology, Morgan Stanley, FTS International, and Crown Crafts — New Horizons, Emerging Trends, and Upcoming Developments
  6. Aeglea: 3Q Earnings Snapshot
  7. Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
  8. Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference
  9. Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
  10. Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
  11. FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency
  12. Is Now The Right Time To Invest In Healthcare And Aeglea BioTherapeutics Inc (NASDAQ:AGLE)?
  13. Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
  14. Aeglea Plunges On Updated Data For Arginase 1 Deficiency Candidate, Wells Fargo Downgrade
  15. George Soros Bought This Under-the-Radar Biotech Stock: Should You?

SEC Filings

  1. 8-K - Current report 181229393
  2. 8-K - Current report 181228818
  3. 8-K - Current report 181207030
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168246
  5. 8-K - Current report 181168223
  6. 8-K - Current report 181131547
  7. 8-K - Current report 181125393
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 181117538
  9. 8-K - Current report 181114950
  10. DEF 14A - Other definitive proxy statements 181058140